Contact
searchSearch
HMP Global
Login

Schizophrenia Topic Center

stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two illustrated heads in profile, one orange and one blue, with slight overlap between the two in the middle of the picture
News
Researchers Advise Screening for Manic Symptoms in Patients With Schizophrenia
02/25/2025
Jolynn Tumolo
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct...
02/25/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
A person sits holding a pill in one hand and a glass of water in the other
News
Iclepertin Shows No Benefit for Cognitive Function in Schizophrenia
01/23/2025
Brionna Mendoza
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial...
01/23/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
Brionna Mendoza
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Prodromal Symptoms in Schizophrenia
12/18/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/18/2024
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Analysis Estimates 0.45% Schizophrenia Prevalence in United States
12/10/2024
Jolynn Tumolo
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia...
12/10/2024
Psych Congress Network
woman schizophrenia depression smart phone
News
Cognitive Symptoms May Be as Burdensome as Psychosis for Patients Living With Schizophrenia
12/04/2024
Brionna Mendoza
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with...
12/04/2024
Psych Congress Network
A doctor looks at a brain scan
Quiz
TBI and Schizophrenia Risk
11/19/2024
Do you know how to care for this patient population? Find out with a quick quiz!
Do you know how to care for this patient population? Find out with a quick quiz!
Do you know how to care for this...
11/19/2024
Psych Congress Network
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
Jolynn Tumolo
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network

News

stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two illustrated heads in profile, one orange and one blue, with slight overlap between the two in the middle of the picture
News
Researchers Advise Screening for Manic Symptoms in Patients With Schizophrenia
02/25/2025
Jolynn Tumolo
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct symptoms of mania in more than a quarter of stable outpatients with schizophrenia spectrum disorders (SSD), according to a study published in Brain Medicine.
Screening revealed distinct...
02/25/2025
Psych Congress Network
A person sits holding a pill in one hand and a glass of water in the other
News
Iclepertin Shows No Benefit for Cognitive Function in Schizophrenia
01/23/2025
Brionna Mendoza
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial evaluating the efficacy of iclepertin (BI 425809), a glycine transporter-1 inhibitor, in treating cognitive impairment associated with schizophrenia (CIAS) showed no significant differences in cognitive outcomes...
A Phase II clinical trial...
01/23/2025
Psych Congress Network
brain waves schizophrenia transcranial magnetic stimulation
News
Review Questions Utility of tDCS for Cognitive Symptoms in Schizophrenia
01/08/2025
Brionna Mendoza
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions the effectiveness of transcranial direct current stimulation (tDCS) for improving cognitive impairments in individuals with schizophrenia after finding no statistically significant difference in cognitive...
A recent meta-analysis questions...
01/08/2025
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Analysis Estimates 0.45% Schizophrenia Prevalence in United States
12/10/2024
Jolynn Tumolo
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia are covered by Medicare and Medicaid compared with commercial payers in the United States, according to results from a 2022 claims analysis presented in a poster at Psych Congress. “Among the Medicaid...
More patients with schizophrenia...
12/10/2024
Psych Congress Network
woman schizophrenia depression smart phone
News
Cognitive Symptoms May Be as Burdensome as Psychosis for Patients Living With Schizophrenia
12/04/2024
Brionna Mendoza
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with schizophrenia discussed cognitive symptoms of the disease less often than psychotic symptoms, cognitive and other negative symptoms were “perceived” as “equally burdensome” as the positive symptoms of the disease due to...
Patients living with...
12/04/2024
Psych Congress Network
a caregiver speaks with a doctor
News
Caregivers Confirm Usability of Schizophrenia Cognition Rating Scale
11/14/2024
Jolynn Tumolo
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving unpaid and professional caregivers of patients with schizophrenia confirmed the content and usability of the Schizophrenia Cognition Rating Scale (SCoRS).
A qualitative study involving...
11/14/2024
Psych Congress Network
Conference presenter
News
Olanzapine/Samidorphan Demonstrates Favorable Safety Profile in 4-Year Open-Label Study
11/01/2024
Brionna Mendoza
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination olanzapine/samidorphan (OLZ/SAM) maintained consistent symptom control in patients with schizophrenia or bipolar I disorder and demonstrated a favorable long-term safety profile over 4 years consistent with previous studies.
Combination...
11/01/2024
Psych Congress Network
dr and patient with brain model
News
Rehospitalization Risk, Treatment Costs Lower With Continued/Maintenance ECT
10/08/2024
Jolynn Tumolo
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive therapy (ECT) after an acute ECT series is linked with lower rehospitalization risk compared with not continuing ECT, according to study results published in JAMA Psychiatry.
Continuing electroconvulsive...
10/08/2024
Psych Congress Network
A midlife woman sits on a couch and looks out the window with her chin resting on her fist.
News
Menopausal Hormone Therapy Benefits Midlife Women With Schizophrenia
10/04/2024
Jolynn Tumolo
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT) is associated with a 16% lower risk of psychosis relapse in midlife women with schizophrenia or schizoaffective disorder (SSD).
Menopausal hormone therapy (MHT)...
10/04/2024
Psych Congress Network
Study on MDD - stock image
News
Phase II Trial of AL001 for MDD Set to Begin Later this Year
03/24/2025
Jolynn Tumolo
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a phase II clinical study of investigational lithium therapy AL001 for MDD, focusing on its unique properties and its effect on lithium delivery in the brain compared with marketed lithium salts.
Plans have been announced for a...
03/24/2025
Psych Congress Network
US FDA sign
News
FDA Seeks Clearer Labeling for Transmucosal Buprenorphine Product Dosing
03/24/2025
Jolynn Tumolo
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that current labeling for buprenorphine-containing transmucosal products includes a maximum daily dose, the US Food and Drug Administration (FDA) is encouraging the submission of supplemental new drug applications to...
To avoid misperceptions that...
03/24/2025
Psych Congress Network
3 medical professionals stand together talking in the hallway of a medical facility
News
Accelerated Theta-Burst Stimulation Protocol Improves Treatment-Resistant Depression
03/21/2025
Jolynn Tumolo
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated theta-burst stimulation (aTBS) protocol reduced depression severity in patients with treatment-resistant depression (TRD), according to results from a randomized clinical trial published in JAMA Psychiatry.
A novel 78-minute accelerated...
03/21/2025
Psych Congress Network
an older man wearing glasses rubs his face in stress tired depression treatment resistant depression
News
Genetic Predispositions to Insomnia, Neuroticism, Linked With Higher Risk for Treatment-Resistant Depression
03/18/2025
Jolynn Tumolo
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to traits including neuroticism, cognitive function, and sleep patterns were significantly associated with the development of treatment-resistant depression (TRD) in a cohort study published in JAMA Psychiatry.
A genetic predisposition to...
03/18/2025
Psych Congress Network
Woman sitting at bar holding a drink.
News
Semaglutide Reduces Cravings in Adults with Alcohol Use Disorder
03/13/2025
Jolynn Tumolo
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose semaglutide decreased the amount of alcohol consumed, relative to placebo, in a laboratory test involving adults with AUD who were not seeking treatment, study finds.
Nine weeks of low-dose...
03/13/2025
Psych Congress Network
emergency room hospital waiting room reception area
News
Why Aren’t More Emergency Departments Using Medications for OUD Treatment?
03/12/2025
Jolynn Tumolo
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the use of medications for opioid use disorder (MOUD) in US emergency departments (EDs), according to results from a systematic review published in the Journal of Substance Use & Addiction Treatment.
Barriers may be hampering the...
03/12/2025
Psych Congress Network
stethoscope with research images in background medical study clinical trial research
News
Machine Learning Predicts Progression to Schizophrenia Within 5 Years
03/12/2025
Jolynn Tumolo
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used routine clinical data from electronic health records to predict progression to schizophrenia and bipolar disorder within 5 years for patients with pre-existing mental illness, according to a study published in...
Machine learning models used...
03/12/2025
Psych Congress Network
two researchers look at computer screen in lab medical research
News
Continuous D2 Blockade in First-Episode Schizophrenia Does Not Raise Relapse Risk
03/05/2025
Jolynn Tumolo
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous treatment with dopamine D2 receptor-blocking long-acting injectable (LAI) antipsychotics does not appear to increase the risk of breakthrough psychosis in patients with first-episode schizophrenia.
More than 5 years of continuous...
03/05/2025
Psych Congress Network
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
A woman lies on the couch holding an ice pack to her head
News
Mild TBI Sustained in Traumatic Context Associated With Worse Long-Term Outcomes
03/03/2025
Jolynn Tumolo
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury (mTBI) that occurred in the context of psychological trauma was associated with poorer long-term outcomes, including greater posttraumatic stress disorder (PTSD) severity, postconcussive symptoms, and disability.
Mild traumatic brain injury...
03/03/2025
Neurology

Quizzes

Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
Prodromal Symptoms in Schizophrenia
12/18/2024
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
12/18/2024
Psych Congress Network
A doctor looks at a brain scan
Quiz
TBI and Schizophrenia Risk
11/19/2024
Do you know how to care for this patient population? Find out with a quick quiz!
Do you know how to care for this patient population? Find out with a quick quiz!
Do you know how to care for this...
11/19/2024
Psych Congress Network
Jonathan Meyer
Quiz
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments?
10/23/2024
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine receptor activators differ from traditional antipsychotic treatments? Take the quiz to find out!
How do muscarinic acetylcholine...
10/23/2024
Psych Congress NP Institute
quiz
Quiz
Which symptoms of schizophrenia must be present to make a diagnosis?
06/21/2024
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic symptoms of schizophrenia must be present for a diagnosis to be made. At least one of these must be which of the following, according to the DSM-5-TR? Take the quiz!
Two of the 5 characteristic...
06/21/2024
Psych Congress Network
In an illustrated cartoon style, a man sits on the ground with his head in his hands
Quiz
Global Schizophrenia Care Rates
04/15/2024
Put your knowledge to the test with this quick quiz!
Put your knowledge to the test with this quick quiz!
Put your knowledge to the test...
04/15/2024
Psych Congress Network
Psych Congress Network Quiz
Quiz Series
Decoding Psychotic Symptoms in Schizophrenia Part 2
12/15/2023
Which term refers to a psychotic symptom experienced with schizophrenia characterized by strong beliefs that are not true and may seem irrational to others? Take the quiz!
Which term refers to a psychotic symptom experienced with schizophrenia characterized by strong beliefs that are not true and may seem irrational to others? Take the quiz!
Which term refers to a psychotic...
12/15/2023
Psych Congress Network
quiz
Quiz
Decoding Psychotic Symptoms in Schizophrenia Part 1
12/05/2023
Which term refers to a psychotic symptom experienced with schizophrenia characterized by unusual or illogical ways of thinking, difficulty organizing thoughts and speech, stopping mid-thought, or jumping between unrelated topics?
Which term refers to a psychotic symptom experienced with schizophrenia characterized by unusual or illogical ways of thinking, difficulty organizing thoughts and speech, stopping mid-thought, or jumping between unrelated topics?
Which term refers to a psychotic...
12/05/2023
Psych Congress Network
How many adults does schizophrenia affect globally?
Quiz
How many adults does schizophrenia affect globally?
11/14/2023
Do you think you know this statistic?
Do you think you know this statistic?
Do you think you know this...
11/14/2023
Psych Congress Network
Quiz question clip art schizophrenia
Quiz
Schizophrenia Prognosis in Men Compared With Women
11/03/2023
T or F: According to the DSM-5-TR, men have more prominent negative symptoms, cognitive impairment, and generally worse functional outcomes than women.
T or F: According to the DSM-5-TR, men have more prominent negative symptoms, cognitive impairment, and generally worse functional outcomes than women.
T or F: According to the...
11/03/2023
Psych Congress Network
Dr Steven Chan
Expert Insights Quiz
Choosing the Right Digital Therapeutic for MDD Treatment
03/18/2025
Steven Chan, MD, MBA; Meagan Thistle
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress Steering Committee Member Steven Chan, MD, MBA, which of the following are important considerations when selecting and implementing digital therapeutics for the treatment of MDD?
According to Psych Congress...
03/18/2025
Psych Congress Network
Did OUD diagnoses increase or decrease in VHA patients?
Quiz
Did OUD diagnoses increase or decrease in VHA patients?
02/25/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/25/2025
Psych Congress Network
Charles Raison headshot
Expert Insights Quiz
First-Line Treatment Options for Insomnia
02/21/2025
Charles L. Raison, MD
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to Psych Congress Steering Committee Member, Charles Raison, MD, the first-line treatment for primary insomnia is medication, including benzodiazepines.
True or False: According to...
02/21/2025
Psych Congress Network
Quiz
Quiz
Cariprazine FDA-Approved Indications
02/21/2025
Meagan Thistle
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as an adjunctive treatment for major depressive disorder (MDD)? What is another FDA-approved indication for this drug? Take the quiz to test your psychopharmacology knowledge!
Is cariprazine FDA-approved as...
02/21/2025
Psych Congress Network
How many US Psychiatric Hospitals Provided Medications for OUD?
Quiz
How many US psychiatric hospitals provided medications for OUD?
02/06/2025
Do you remember the details of this study?
Do you remember the details of this study?
Do you remember the details of...
02/06/2025
Psych Congress Network
Four people ponder with question marks over their heads
Quiz
DSM-5 Quiz: Mood Symptoms in Schizophrenia
02/03/2025
Test your knowledge with this quick quiz!
Test your knowledge with this quick quiz!
Test your knowledge with this...
02/03/2025
Psych Congress Network
How many people with anxiety disorders receive treatment?
Quiz
How many people with anxiety disorders receive treatment?
01/28/2025
Test your statistical knowledge!
Test your statistical knowledge!
Test your statistical knowledge!
01/28/2025
Psych Congress Network
How can clinicians help patients with ADHD transition from adolescence to adulthood?
Quiz
How can clinicians help patients with ADHD transition from adolescence to adulthood?
01/22/2025
Do you remember this interview with Dr Wilens?
Do you remember this interview with Dr Wilens?
Do you remember this interview...
01/22/2025
Psych Congress Network
Three illustrated faces, one sad, one neutral, one happy, with a human hand picking up the happy face
Quiz
Conditions That Mimic ADHD in Pediatric Patients
01/21/2025
Test your knowledge with this quiz!
Test your knowledge with this quiz!
Test your knowledge with this...
01/21/2025
Psych Congress Network
Quiz
Quiz
What percentage of people experience hypomanic symptoms during an MDD episode?
01/15/2025
Meagan Thistle
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study published in the Journal of Affective Disorders, what percentage of people experienced hypomanic symptoms during a major depressive disorder (MDD) episode?
According to a recent study...
01/15/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use